Single-lesion leprosy poses a unique problem for India in view of the adopted strategy of active case-detection. The proportion of single-lesion patients among the newly detected cases varies among states from 5% to more than 50%. It must be noted that, in a sizeable proportion of patients, single-lesion leprosy is thought to undergo spontaneous self-healing. In addition, there are problems regarding diagnostic specificity of this variety of leprosy. It was considered quite acceptable to conduct a trial of single-dose therapy with the combination rifampicin-ofloxacin-minocyc1ine (ROM) among patients with single-lesion paucibacillary (PB) leprosy; rifampicin is strongly bactericidal, and the concurrent administration of ofloxacin and minocycline was expected to prevent selection of rifampicin-resistant mutant My cobacterium leprae. Therefore, a large multicentre field trial involving 1483 PB leprosy patients with single lesions was conducted in India to study the efficacy of a single dose of ROM. l The trial, sponsored by the World Health Organization (WHO), was a placebo controlled, randomized, double-blind study involving nine different centres in India.
Complete cure (%) 46·9 54·7 0·004
* The probability that the observed difference between the two treatment groups occurred by chance.
regimens were also compared with respect to complete cure; 46·9% of those administered ROM and 54·7% of those administered the standard WHO PB regimen demonstrated complete cure, a significant difference. Self-healing of single-lesion leprosy and questionable diagnostic specificity, which may be considered confounding factors, would be expected to lead to an underestimate of the efficacy of the standard regimen in comparison to that of ROM. Even so, the results of treatment by ROM were still very promising. On the basis of these promising results, the National Leprosy Eradication Programme decided to employ a single dose of ROM as standard treatment for Indian patients with single-lesion leprosy.
Trial of a single dose of ROM for PB leprosy with only two or three lesions After successful completion of the trial of single-dose ROM for single-lesion patients, the decision was taken to apply almost the same protocol in a WHO-sponsored, multicentre, double-blind trial of single-dose ROM and standard WHO PB MDT for 6 months among PB patients with only two or three lesions. For this trial, 236 patients, 163 adults and 73 children, were recruited between October 1995 and April 1996. Ninety-two percent of the patients completed 6 months of treatment, and approximately 90% of the patients were followed for 18 months. The patients who did not complete treatment were equally distributed between the two regimens. As shown in Table 2 , clinical scores at intake were very similar among the patients of both treatment groups, and decreased to about the same degree in both groups; the differences observed were not statistically significant at any interval. Approximately 50% of the patients of both groups showed marked clinical improvement, and complete clearance of lesions was observed in approximately 40% of the patients of both treatment groups; here, too, the observed differences were not statistically significant. Four patients of each group were judged to represent treatment failure, because they demonstrated no clinical improvement, were found to be smear-positive, or exhibited new lesions. Thus, although the sample size for this trial was much smaller than that for the single-lesion trial, the results were similar.
Additional analyses of various subgroups of patients, also summarized in Table 2 , are worth mention. Among patients with involvement of only a single body part, the efficacy of standard WHO PB MDT was very similar to that of ROM, as judged by complete clearance of lesions. However, when two or more body parts were affected, the difference between the regimens was remarkable. Of the 26 patients with involvement of two or more body parts who were treated by standard WHO PB MDT, 13 had complete clearance, compared with only six of 30 such patients who were administered ROM. Thus, if two or more body-parts are affected, i.e. the disease is more extensive, standard WHO PB MDT may be indicated. However, because the number of patients included in this trial is small, no definite conclusions should be drawn.
Single dose for all PB leprosy patients
In both of these trials, follow-up of patients was continued for only 18 months. Moreover, the sample size, particularly in the trial of patients with two or three lesions, was not very large. For these reasons, we have no information on relapses following treatment by ROM. However, this information is vital.
The possibility was also considered of prescribing the same regimen for all PB leprosy patients. In leprosy control programmes, the majority of all the newly diagnosed PB patients demonstrate from one to three lesions, whereas only a small proportion of the patients demonstrate more than three lesions. Therefore, it was decided to undertake a new trial among all PB leprosy patients with from two to five skin lesions. Of 1592 patients who were recruited for this WHO-sponsored trial between April 1998 and October 1999, about 95% have completed six months treatment. In addition, approximately 1500 patients with single lesions were recruited for an open trial of ROM therapy. The total duration of the study will be 4 years. We expect these two trials to generate information on both cure and relapse rates.
